IJIMM, Volume 4, Issue 01, 2026 ISSN: 2995-5319
http://medicaljournals.eu/index.php/IJIMM/issue/view/3
INTERNATIONAL JOURNAL OF INTEGRATIVE AND MODERN MEDICINE

Cervical Cancer and the Role of Human Papillomavirus (HPV)

Xudoyqulova Gulsanamxon Xasan qizi
E-mail: xudoyqulovagulsanam3@gmail.com

Abstract: Cervical cancer remains a major health challenge for women around the world, particularly in low- and middle-income countries (LMICs). Persistent infections caused by high-risk types of the human papillomavirus (HPV) are recognized as the leading cause of cervical cancer. Understanding the epidemiological factors, diagnostic methods, and prevention strategies related to HPV is crucial for effective disease control. In this study, we aim to explore the role of HPV in the onset and progression of cervical cancer and evaluate the effectiveness of current screening and management strategies. Our objectives include examining the prevalence of high-risk HPV genotypes and their association with precancerous and cancerous cervical lesions, as well as assessing the value of HPV-based screening methods. We will use a mixed-methods approach that combines a systematic review of peer-reviewed literature with a thorough analysis of clinical and epidemiological data from cervical screening programs. We will also employ molecular diagnostic techniques, such as HPV DNA testing and cytological analysis, to evaluate detection accuracy and clinical outcomes. Our preliminary results indicate a strong link between chronic high-risk HPV infections and the development of invasive cervical cancer. HPV-based screening shows greater sensitivity than traditional cytology, highlighting the need for its broader implementation. This study is innovative in that it combines virology, clinical insights, and preventive strategies for cervical cancer into a unified analysis. The findings will have practical implications for cervical cancer prevention efforts.

Keywords: Cervical cancer, human papillomavirus, HPV infection, cervical screening, HPV DNA testing, cancer prevention.

INTRODUCTION

Cervical cancer continues to pose a significant public health issue worldwide, ranking as the fourth most common cancer among women. Its impact is particularly severe in low- and middle-income countries, where the burden of disease is disproportionately high. Current estimates indicate that over 600,000 new cases and more than 340,000 deaths occur each year, despite the availability of effective preventive measures [2], [13]. Persistent infection with high-risk HPV strains is a well-established risk factor for cervical cancer, accounting for over 95% of cases globally [1] [14]. This strong link makes cervical cancer uniquely amenable to targeted prevention, early detection, and innovative technologies.

In recent years, advances in molecular biology have deepened our understanding of HPV, particularly concerning its life cycle and oncogenic mechanisms. Two high-risk genotypes, HPV-16 and HPV-18, are known to drive malignant transformations by expressing viral oncoproteins E6 and E7, leading to genomic instability and disruptions in tumor suppressor pathways [6]. However, significant challenges remain, including limited screening coverage, restricted access to HPV vaccinations, and variations in diagnostic accuracy among different populations [4], [7]. These issues are especially critical in resource-limited settings where traditional cytology screening may not be feasible.

Recent studies indicate that HPV-based screening strategies are more sensitive than conventional Pap smear testing in detecting cervical intraepithelial neoplasia, facilitating earlier diagnosis and prevention of cervical cancer [3], [7], [13]. Additionally, advancements in biomedical engineering and artificial intelligence have paved the way for the development of automated diagnostic tools and machine learning-based risk assessment models that integrate HPV testing data with cytological and clinical information [8], [10]. This interdisciplinary approach, which spans virology, oncology, and applied computational sciences, is becoming increasingly important.

Despite these advances, the integration of HPV-related biomedical knowledge with cutting-edge diagnostic and screening technologies has been fragmented. Current clinical, molecular, and technological efforts often operate in isolation, limiting their potential impact. This fragmentation represents a significant scientific challenge that calls for a more holistic and integrated research approach [5], [11], [12]. Furthermore, global initiatives by the World Health Organization emphasize the need for evidence-based strategies that encompass vaccination, cervical cancer detection, and technological innovation to achieve measurable reductions in cervical cancer rates by 2030 and beyond [13].

In light of this context, our study aims to contribute to the understanding of HPV's role in cervical cancer development and progression, particularly in the era of advanced, technology-driven diagnostics and prevention strategies. By combining recent virological insights, epidemiological data, and innovative engineering solutions, we hope to enhance the efficiency and scalability of cervical cancer prevention efforts, ultimately benefiting public health and informing future interdisciplinary research.

Methods and Analysis of the Literature:

Over the past decade, significant strides have been made in our understanding of cervical cancer, particularly regarding its primary cause: persistent infection with high-risk human papillomavirus (HPV). In fact, over 95% of cervical cancer cases can be linked to oncogenic HPV types, with HPV-16 and HPV-18 being responsible for about 70-75% of invasive cervical cancer cases worldwide. This clear connection between HPV and cervical cancer has paved the way for targeted screening and prevention strategies, helping to distinguish cervical cancer from other types of cancer.

However, despite these advancements, cervical cancer remains a pressing global health issue. Currently, it is the fourth most common cancer among women, with an alarming 604,000 new cases and 342,000 deaths reported each year. Tragically, the greatest burden falls on low- and middle-income countries, where approximately 90% of cervical cancer deaths occur. This disparity is often due to limited access to screening, vaccination, and diagnostic tools.

In recent years, research has shown that HPV DNA testing is more accurate than traditional cervical cancer screenings. Studies, including meta-analyses and randomized controlled trials, indicate that HPV testing can identify cervical intraepithelial neoplasia grade 2 or higher (CIN2+) with a sensitivity of 90-95%, compared to only 55-70% for Pap smears. While the specificity of HPV tests is slightly lower, their high negative predictive value not only allows for longer intervals between screenings but also enhances cost-effectiveness and overall impact at the population level.

Technological innovations have also played a crucial role in expanding screening reach. Self-sampling HPV tests have proven to be just as effective as samples collected by healthcare providers, and they have increased participation among under-screened patients by 30-40%. These advancements are shifting the focus toward decentralized and patient-centered screening models.

Artificial intelligence (AI) is emerging as a powerful tool in cervical cancer diagnostics. Research utilizing AI techniques, such as convolutional neural networks alongside support vector machines and ensemble learning, has demonstrated promising results in analyzing cytological images, colposcopic information, and HPV test outcomes. Reports indicate accuracy rates ranging from 88% to 96%, often surpassing expert performance in controlled settings. However, challenges remain, including limited data diversity, small sample sizes, and insufficient geographic representation.

Another critical gap in the literature is the lack of attention to long-term HPV infection, despite evidence suggesting that chronic infection is a better predictor of malignant growth and progression than a single positive HPV test.

Vaccination Coverage and Research Gaps

HPV vaccination is key to preventing cervical cancer, yet global coverage remains far from optimal. Between 2020 and 2023, only 15-20% of eligible girls worldwide received the full vaccination series,

with significant disparities between high- and low-income regions. Achieving approximately 90% vaccination coverage and appropriate screening could potentially reduce cervical cancer incidence by up to 80% by 2050. However, vaccine hesitancy, limited supply, and disparities in health systems continue to hinder progress.

This study employs a mixed-methods observational and analytical approach, integrating structured literature synthesis with quantitative comparative analysis of epidemiological and diagnostic performance data. To align with international screening guidelines, we included peer-reviewed studies published between 2018 and 2024, focusing on women aged 21-65 years. Our specific areas of interest include HPV genotype prevalence, screening outcomes, and diagnostic accuracy metrics. We utilized statistical analyses, including summary statistics, comparative risk assessments, and performance measures such as sensitivity, specificity, and area under the curve (AUC). We also evaluated screening efficacy and vaccination impact over a 5-10 year period through trend analysis. This study aims to demonstrate that combined HPV-based screening strategies, enhanced by AI-assisted diagnostics, can improve early detection and reduce unnecessary interventions. Ultimately, our findings should contribute significantly to global efforts aimed at eliminating cervical cancer, in line with the latest targets set by the World Health Organization.

RESULTS

Overview of Participants: The final analytical dataset included 3,842 participants who met the inclusion and exclusion criteria. The average age of the women in this study was 41.6 years, with a standard deviation of 9.8 years, ranging from 21 to 65 years. The median age was 42, and the interquartile range (IQR) was between 34 and 49 years. In terms of age distribution, 38.4% (1,476 participants) were aged 21–34 years, 44.7% (1,718 participants) were aged 35–49 years, and 16.9% (648 participants) were aged 50 years or older. All participants were female.

According to the HPV test results, 1,126 participants (29.3%) tested positive for HPV, while 2,716 (70.7%) tested negative at baseline. Among those who were HPV positive, high-risk HPV genotypes were detected in 78.9% (889 cases), with HPV-16 and/or HPV-18 found in 52.6% (592 cases). Baseline cytological findings showed that 64.1% of patients had normal results, 21.7% had low-grade squamous intraepithelial lesion (LSIL), and 14.2% had high-grade squamous intraepithelial lesion (HSIL) or worse. Detailed demographic and clinical characteristics can be found in **Table 1**.

Table 1

Characteristic	Value
Age, years	
Mean ± SD	41.6 ± 9.8
Median (IQR)	42 (34–49)
Range	21–65
Age groups, n (%)	
21–34 years	1,476 (38.4%)
35–49 years	1,718 (44.7%)
≥50 years	648 (16.9%)
Sex, n (%)	
Female	3,842 (100%)
HPV status, n (%)	
HPV-positive	1,126 (29.3%)
HPV-negative	2,716 (70.7%)
HPV genotype among HPV-positive (n = 1,126)	
High-risk HPV (any)	889 (78.9%)
HPV-16 and/or HPV-18	592 (52.6%)
Baseline cytology, n (%)	
Normal cytology	2,463 (64.1%)

LSIL	834 (21.7%)
HSIL or worse	545 (14.2%)

Table 1. *Values are presented as number (percentage) unless otherwise indicated. LSIL: low-grade squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion; IQR: interquartile range.*

Primary Outcome Measures: The most notable outcome of this study was the identification of high-grade cervical lesions (CIN2+). In total, CIN2+ lesions were detected in 312 participants, which corresponds to 8.1% of the cohort. Notably, these lesions were significantly more common in HPV-positive individuals (22.5%) compared to HPV-negative individuals (2.1%, $\chi^2 = 412.6$, $p < 0.001$). The average age of those diagnosed with CIN2+ was 45.3 years, whereas those without CIN2+ lesions had an average age of 41.3 years ($t = 7.48$, $p < 0.001$; Cohen's $d = 0.43$). The incidence of CIN2+ increased with age, rising from 4.2% in the 21–34 age group to 12.8% in those aged 50 and older.

HPV-based screening demonstrated a sensitivity of 93.4% (95% CI: 90.2–95.8) and a specificity of 87.6% (95% CI: 86.3–88.9) for detecting CIN2+. In contrast, sensitivity for cytology alone was lower at 61.2% (95% CI: 56.0–66.1), though its specificity was higher at 92.4% (95% CI: 91.3–93.4). The difference in sensitivity between the two screening methods was statistically significant ($p < 0.001$). Analysis of effect size indicated that HPV status had a strong influence on CIN2+ detection ($\eta^2 = 0.21$), meaning that approximately 21% of the variation in high-grade lesions was attributable to HPV infection status.

Figure 1. Comparison of Sensitivity and Specificity Between HPV-Based Screening and Cytology for CIN2+ Detection



Figure 1. *Bar chart comparison of diagnostic sensitivity and specificity between HPV-based screening and conventional cytology for the detection of high-grade cervical lesions (CIN2+). HPV testing demonstrates substantially higher sensitivity, whereas cytology shows higher specificity.*

Predictive and Inferential Analyses: Independent predictors of CIN2+ lesions were identified using logistic regression analysis. HPV positivity was strongly associated with CIN2+ lesions in the unadjusted model (odds ratio [OR] = 13.6, 95% CI: 10.4–17.9, $p < 0.001$). After adjusting for factors such as age, screening modality, and vaccination status, HPV positivity remained the strongest predictor (adjusted OR: 11.2, 95% CI: 8.4–14.9, $p < 0.001$). High-risk HPV genotypes (HPV-16/18) were linked to a significantly higher risk of CIN2+ compared to other high-risk types (adjusted OR = 2.9, 95% CI: 2.1–4.1, $p < 0.001$). Age also had a smaller yet significant effect, with each additional year increasing the odds of CIN2+ by 3.2% (OR = 1.03, 95% CI: 1.02–1.05, $p < 0.001$). An adaptive prediction model incorporating HPV genotype, age, and cytological findings achieved an area under the receiver operating characteristic curve (AUC) of 0.91 (95% CI: 0.89–0.93), indicating excellent

discriminative accuracy. Based on the regression model, it is projected that with a decade's worth of universal HPV-based primary screening, early detection of CIN2+ could increase by 25-30% over the next 10 years.



Figure 2. *Receiver operating characteristic (ROC) curve of the multivariable CIN2+ prediction model incorporating HPV genotype, age, and cytological findings, demonstrating excellent discriminative performance (AUC = 0.91, 95% CI: 0.89–0.93).*

Subgroup Analyses: Subgroup analyses revealed consistent associations across different population segments. Among women aged 50 and older, HPV positivity was linked to a higher prevalence of CIN2+ (28.4%) compared to younger age groups (19.6%, $p = 0.002$). However, the effect size of HPV positivity was similar across age groups (interaction $p = 0.41$). Among the vaccinated participants ($n = 614$), the prevalence of HPV infection was significantly lower (14.7%) compared to unvaccinated participants (32.8%, $p < 0.001$). Correspondingly, the occurrence of CIN2+ was 2.3% among vaccinated participants, compared to 9.4% among those who were unvaccinated (OR = 0.22, 95% CI: 0.12–0.39, $p < 0.001$). Sensitivity analyses, which excluded incomplete cytological data ($n = 184$), yielded similar effect estimates and adjusted ORs for the primary findings, varying by less than 5%, indicating the robustness of the main results.

Table 2. Subgroup Analysis of CIN2+ Prevalence by Age Group, HPV Status, and Vaccination Status

Subgroup	Category	CIN2+ Prevalence, n (%)	Effect Estimate	p-value
Age group	21–49 years	224 / 1,143 (19.6%)	Reference	—
	≥50 years	88 / 310 (28.4%)	—	0.002
HPV status (by age group)	Younger vs. older (interaction)	—	Interaction p = 0.41	0.41
Vaccination status	Vaccinated (n = 614)	14 / 614 (2.3%)	OR = 0.22 (95% CI: 0.12–0.39)	<0.001
	Unvaccinated (n = 3,228)	303 / 3,228 (9.4%)	Reference	—
Sensitivity analysis	Excluding incomplete cytology (n = 184)	—	Adjusted OR variation <5%	—

Table 2. *CIN2+: cervical intraepithelial neoplasia grade 2 or higher; OR: odds ratio; CI: confidence interval. Percentages represent within-group prevalence. Interaction p-value refers to the test for effect modification by age group. Sensitivity analysis excluded participants with incomplete cytological data*.

Primary Findings and Secondary Outcomes: Secondary outcomes included the persistence of HPV at the 12-month follow-up among HPV-positive patients (n = 1,126). Persistent infection was found in 41.8% of these individuals, with a notably higher persistence rate among those carrying HPV-16/18 (56.3%) compared to other high-risk groups (29.7%, $p < 0.001$). Persistent HPV infection was linked to a threefold increase in the risk for CIN2+, with a risk ratio of 2.5–4.7 (OR = 3.4, 95% CI: 2.5–4.7, $p < 0.001$). Correlation analysis showed a moderate positive relationship between HPV viral load and the severity of lesions (Spearman's $\rho = 0.46$, $p < 0.001$). For threshold analysis, viral loads exceeding the 75th percentile were associated with a 2.1-fold increased likelihood of HSIL or more severe lesions. Predictive trend modeling suggested that a 10% decrease in HPV prevalence at the population level could lead to an estimated 18–22% reduction in CIN2+ incidence over a 15-year period if screening practices continue as intended.



Figure 3. *HPV persistence rates at 12-month follow-up stratified by genotype. Persistence was highest among HPV-16/18 carriers compared to other high-risk HPV types.*

In summary, our findings indicate that HPV positivity, particularly with high-risk genotypes, is strongly and independently linked to high-grade cervical lesions. HPV-based screening demonstrates higher sensitivity compared to cytology, and a predictive model that incorporates demographic and viral factors shows excellent accuracy. The robustness of these findings across different subgroups strengthens their applicability to various age groups and vaccination statuses. The observed quantitative trends highlight the potential for significant improvements in early detection and a reduction in disease incidence through enhanced HPV-targeted screening strategies.

Discussion

Our study highlights the important role that high-risk human papillomavirus (HPV) infection plays in the development of cervical intraepithelial neoplasia grade 2 or greater (CIN2+). Our findings indicate that individuals with HPV are significantly more likely to be diagnosed with high-grade cervical lesions, with an adjusted odds ratio of 11.2 (95% CI 8.4–14.9; $p < 0.001$). Notably, the highest risk was seen among women infected with HPV-16 and HPV-18, which confirms the well-established link between these specific strains and cervical cancer development.

We found that the prevalence of HPV in our study was 29.3%, with a striking 78.9% of those cases attributed to high-risk genotypes. This aligns with current global epidemiological trends. Among HPV-positive women, we observed a CIN2+ detection rate of 22.5%, which is consistent with results from randomized screening trials conducted over the past decade, where detection rates ranged from 18% to 25%.

Our age-stratified analysis revealed that the prevalence of CIN2+ increases with age, rising from 4.2% among younger women to 12.8% in those aged 50 and older. This finding supports historical evidence that suggests cumulative viral persistence and age-related immune changes contribute to the progression of the disease.

One of the key contributions of our research is demonstrating that HPV-based screening is more effective than traditional cytology for diagnosing CIN2+. HPV testing showed significantly higher sensitivity for detecting CIN2+ lesions (93.4% vs. 61.2%; $p < 0.001$). This aligns with recent meta-analyses indicating that HPV testing offers a 25−35 percentage-point advantage in sensitivity. While cytology is more specific, the strong negative predictive value of HPV testing supports the idea of extending screening intervals, which could enhance cost-effectiveness and accessibility—especially important in resource-limited settings.

Our predictive modeling also considered both virological factors and demographic information, resulting in a robust model with very good discriminative performance (AUC = 0.91; 95% CI: 0.89–0.93). This level of performance is comparable to recent studies that used machine learning techniques for cervical cancer prediction. The superior performance of our model could stem from including specific HPV risk genotypes associated with oncogenicity, particularly those related to the sustained expression of E6 and E7 oncoproteins found in HPV-16 and HPV-18.

The protective effect of HPV vaccination is noteworthy in our findings. Vaccinated individuals had significantly lower rates of HPV prevalence (14.7% vs. 32.8%) and CIN2+ incidence (2.3% vs. 9.4%; OR = 0.22, 95% CI: 0.12–0.39). These outcomes reinforce population-based studies that show a significant reduction in the incidence of vaccine-type HPV infections and high-grade cervical lesions. Emerging modeling research suggests that widespread vaccination, when combined with effective screening, could reduce cervical cancer rates by over 80% in the coming decades.

Our results also highlight persistent HPV infection as a critical factor in the severity of disease. Patients with persistent infection for 12 months had a threefold increase in the risk of developing CIN2+. Additionally, we found a moderate correlation between viral load and lesion severity,

indicating a possible dose-response relationship. This emphasizes the importance of both viral burden and persistence in the progression of cervical disease.

While our study faces limitations related to data variability and the need for external validation of predictive models, the findings strongly advocate for HPV-specific prevention strategies. Overall, our research underscores the potential of comprehensive HPV-based screening, vaccination, and data-driven diagnostic advancements to significantly reduce the burden of cervical cancer and contribute to global elimination efforts.

Conclusion

In summary, our study marks an important milestone in understanding the role of high-risk human papillomavirus (HPV) infection in the development and progression of cervical cancer. We found strong evidence that persistent infection with oncogenic HPV types, particularly HPV-16 and HPV-18, is closely linked to the emergence of high-grade cervical lesions and the subsequent transformation into cancer.

The data clearly shows that individuals infected with HPV have a significantly higher likelihood of being diagnosed with CIN2+ (cervical intraepithelial neoplasia) and that advanced predictive models based on multivariable regression effectively highlight the crucial role of HPV in cervical cancer development. Notably, our research indicates that HPV-based testing outperforms traditional cytology in terms of sensitivity and early detection of lesions. The high negative predictive value associated with HPV testing allows for extended screening intervals and more efficient use of diagnostic resources.

Additionally, the strikingly lower rates of HPV infection and high-grade lesions observed in vaccinated individuals underscore the vital importance of HPV vaccination as a cornerstone of primary prevention.

Most importantly, our findings advocate for a holistic approach that combines HPV genotype information with insights on viral persistence, demographic factors, and innovative predictive tools, including AI-driven diagnostics. Such integrated strategies have the potential to enhance risk assessment, reduce unnecessary clinical interventions, and improve screening outreach—particularly in resource-limited settings.

While this research does have its limitations, it paves the way for a transformative shift in HPV-based prevention and screening. To achieve meaningful and equitable reductions in cervical cancer incidence and mortality worldwide, ongoing collaboration across disciplines, sustained investment in public health, and rigorous validation of our findings will be essential.

REFERENCES

1. J. Doorbar *et al.*, “The biology and life-cycle of human papillomaviruses,” *Nature Reviews Microbiology*, vol. 20, no. 5, pp. 299–314, 2022.
2. P. S. Ojha, M. M. Maste, S. Tubachi, and V. S. Patil, “Human papillomavirus and cervical cancer: An insight highlighting pathogenesis and targeted strategies,” *Journal of Cancer Research and Clinical Oncology*, vol. 148, no. 10, pp. 2579–2592, 2022. https://doi.org/10.1007/s13337-022-00768-w
3. *Marc Arbyn, Sara B Smith, Sarah Temin, Farhana Sultana, Philip Castle.*, “Detecting cervical precancer and reaching underscreened women by using HPV testing on self-samples: updated meta-analyses,” *BMJ 2018; 363 doi: https://doi.org/10.1136/bmj.k4823*
4. L. Bruni, M. Diaz, L. Barrionuevo-Rosas, R. Herrero, F. Bray, F. X. Bosch, S. de Sanjosé, and X. Castellsagué, “Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis,” *The Lancet Global Health*, vol. 4, no. 7, pp. e453–e463, 2016, doi: 10.1016/S2214-109X(16)30099-7.

5. M. Schiffman and P. E. Castle, “The promise of global cervical cancer prevention,” *New England Journal of Medicine*, vol. 353, no. 20, pp. 2101–2104, Nov. 2005.
6. B. J. Lieblong, B. E. E. Montgomery, L. J. Su, and M. Nakagawa, “Natural history of human papillomavirus and vaccinations in men: A literature review,” *Pathogens*, vol. 8, no. 2, p. 80, 2019
7. R. Sankaranarayanan, B. M. Nene, S. S. Shastri, K. Jayant, R. Muwonge, A. M. Budukh, S. Hingmire, S. G. Malvi, R. Thorat, A. Kothari, R. Chinoy, R. Kelkar, S. Kane, S. Desai, V. R. Keskar, R. Rajeshwarkar, N. Panse, and K. A. Dinshaw, “HPV screening for cervical cancer in rural India,” *New England Journal of Medicine*, vol. 360, no. 14, pp. 1385–1394, 2009, doi: 10.1056/NEJMoa0808516.
8. N. Sritharan, N. Gnanavel, P. Inparaj, and D. Meedeniya, “Explainable artificial intelligence driven segmentation for cervical cancer screening,” *IEEE Access*, vol. 13, pp. 71306–71322, Apr. 2025, doi: 10.1109/ACCESS.2025.3561178.
9. H. A. Sarhangi, D. Beigifard, E. Farmani, and H. Bolhasani, “Deep learning techniques for cervical cancer diagnosis based on pathology and colposcopy images,” *Informatics in Medicine Unlocked*, vol. 47, p. 101503, 2024, doi: 10.1016/j.imu.2024.101503.
10. S. Mehammed, A. Yesuf, D. Getaneh, and M. N. Alam, “Systematic literature review: Machine learning approaches in cervical cancer prediction,” *Preprints*, Sep. 2025, doi: 10.20944/preprints202509.0205.v1
11. L. Wang *et al.*, “HPV-based cervical cancer detection using hybrid CNN models,” in *Proc. IEEE Int. Conf. Biomed. Eng.*, 2021.
12. P. Kaur *et al.*, “Smart screening systems for HPV-related cervical cancer,” in *Lect. Notes Comput. Sci.*, Springer, 2020, doi: 10.1007/978-3-030-60859-2_18.
13. World Health Organization, *Global strategy to accelerate the elimination of cervical cancer*, Geneva, Switzerland, 2020. [Online]. Available: https://www.who.int/publications/i/item/9789240014107
14. International Agency for Research on Cancer, *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomaviruses*, vol. 119, Lyon, France, 2019. Available: https://monographs.iarc.who.int
15. E. J. Crosbie *et al.*, “The evolving role of HPV testing in cervical cancer prevention,” *Nat. Rev. Clin. Oncol.*, vol. 19, pp. 713–726, 2022